论文部分内容阅读
乳腺癌是女性患者最常见的恶性肿瘤之一,25%~30%的乳腺癌患者有人类表皮生长因子受体2(HER-2)基因的过表达[1]。曲妥珠单抗是第一种用于治疗HER-2阳性转移性乳腺癌的人源化单克隆抗体药物,选择性地作用于HER-2的细胞外部位,抑制肿瘤细胞的增殖,其对HER-2阳性乳腺癌患者的确切疗效受到临床欢迎[2]。我科2015年对
Breast cancer is one of the most common malignant tumors in female patients. Over-expression of human epidermal growth factor receptor 2 (HER-2) gene is present in 25% -30% of breast cancer patients. Trastuzumab, the first humanized monoclonal antibody to treat HER-2 positive metastatic breast cancer, selectively acts on extracellular sites of HER-2 and inhibits tumor cell proliferation. The exact efficacy of HER-2-positive breast cancer is clinically welcomed [2]. My section 2015 is right